Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research

BACKGROUND: Despite the introduction of novel effective treatment regimens like gemcitabine plus nab-paclitaxel and FOLFIRINOX, pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive epithelial tumors. Among the genetic alterations frequently found in PDAC, mutations in the KRAS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Baechmann, Sibylle, Ormanns, Steffen, Haas, Michael, Kruger, Stephan, Remold, Anna, Modest, Dominik Paul, Kirchner, Thomas, Jung, Andreas, Werner, Jens, Heinemann, Volker, Boeck, Stefan
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5445280/
https://ncbi.nlm.nih.gov/pubmed/28549417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3376-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados